Vaccination against deltaretroviruses: the bovine leukemia virus paradigm

GUTIERREZ GERONIMO; RODRIGUEZ SABRINA; DE BROGNIEZ ALIX; GILLET NICOLAS; GOLIME RAMARAO; BURNY ARSENE; JAWORSKI JUAN PABLO; ALVAREZ IRENE; VAGNONI LUCAS; TRONO KARINA; WILLEMS LUC

Viruses

MPDI AG

Lugar: Basel; Año: 2014 vol. 20 p. 2416 - 2427

1999-4915

Bovine leukemia virus (BLV) and human T-lymphotropic virus type 1 (HTLV-1)are closely related ?Ô-retroviruses that induce hematological diseases. HTLV-1 infects about 15  million  people  worldwide,  mainly  in  subtropical  areas.  HTLV-1  induces  a  wide spectrum of diseases (e.g.,  HTLV-associated myelopathy/tropical spastic paraparesis) and leukemia/lymphoma (adult T-cell leukemia). Bovine leukemia virus is a major pathogen of cattle, causing important economic losses due to a reduction in production, export limitations and lymphoma-associated death. In the absence of satisfactory treatment for these diseases and  besides  the  prevention  of  transmission,  the  best  option  to  reduce  the  prevalence  of -retroviruses  is  vaccination.  Here,  we  provide  an  overview  of  the  different  vaccination strategies in the BLV model and outline key parameters required for vaccine efficacy.